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Purpose of review:  Optic neuritis is the most common cause of optic neuropathy in 
young adults.  High-dose intravenous corticosteroids (IVCS) were established as the 
standard of treatment for acute optic neuritis via the Optic Neuritis Treatment Trial 
(ONTT), with its first findings published more than 20 years ago.  Subsequent studies 
have further clarified the role of corticosteroids in the treatment of acute optic neuritis. 
Recent findings:  Recent clinical research has confirmed existing knowledge of the 
efficacy and limitations of corticosteroids in the treatment of optic neuritis.  Recent 
studies have examined the role of race, route of administration, and combination of 
IVCS with other therapies.  Current evidence continues to support high-dose IVCS as 
the cornerstone of treatment of acute optic neuritis. 
Summary:  High-dose IVCS are effective in hastening visual recovery in acute typical 
optic neuritis, but do not affect the final visual outcome.  In optic neuritis patients, IVCS 
may delay progression to clinically definite multiple sclerosis (CDMS) at 2 years, but not 
at 5 or 10 years.  It is reasonable to recommend high-dose IVCS for acute optic neuritis 
patients with significant vision loss, severe pain, and/or white matter lesions on brain 
MRI in whom the potential for benefit outweighs the risks. 






CDMS: clinically-definite multiple sclerosis; CRION: chronic relapsing inflammatory optic 
neuropathy; IV: intravenous; IVCS: intravenous corticosteroids; MR: magnetic 
resonance; MRI: magnetic resonance imaging, NMO: neuromyelitis optica; ONTT: optic 
neuritis treatment trial; PLEX: plasma exchange 
 
Introduction 
Optic neuritis is defined as dysfunction of the optic nerve related to inflammation.  It is 
the most common cause of optic neuropathy among young adults and is the presenting 
sign of multiple sclerosis in approximately 20-25% of cases (1).  The clinical hallmarks 
of typical optic neuritis include subacute, central vision loss in one eye that may 
progress over 1-2 weeks, accompanied by pain with eye movements in > 90% of cases, 
a relative afferent pupillary defect in unilateral cases, and impairment of color vision out 
of proportion to visual acuity.  Optic neuritis is a clinical diagnosis, but magnetic 
resonance imaging (MRI) of the brain and orbits is useful, both in confirming the 
presence of optic nerve inflammation and in screening for radiographic evidence of 
multiple sclerosis (Figure 1).  MRI has also proven to be the single best predictor of the 
future risk of multiple sclerosis in patients with optic neuritis (2). 
Since the publication of the Optic Neuritis Treatment Trial (ONTT), a multicenter, 
prospective, randomized, placebo-controlled clinical trial in which intravenous 
corticosteroids (IVCS) and oral steroids were evaluated in patients with acute optic 
neuritis (3), IVCS have been routinely used in the treatment of acute optic neuritis.  The 
  
necessity of treatment of idiopathic demyelinating optic neuritis is debatable, as IVCS 
have been demonstrated to hasten visual recovery and potentially temporarily delay the 
onset of multiple sclerosis, but have failed to show an effect on long-term visual 
outcomes.  The aim of this article is to review recent evidence and offer reasonable 
criteria to guide the use of IVCS in the treatment of acute optic neuritis. 
 
Corticosteroids for Optic Neuritis 
Glucocorticosteroids exert their immunosuppressant effects via a variety of cellular 
mechanisms relevant to optic neuritis, at both genomic and nongenomic levels, with 
effects on blood-brain barrier integrity, leukocyte chemotaxis, immunoglobulin 
production, macrophage activation, and cytokine production, among others (4,5).  
Corticotrophin and cortisone were used with some benefit in a variety of neurologic 
disorders, including optic neuritis, in an uncontrolled study published in 1952, without 
any definite conclusions regarding efficacy (6).  Over the next several decades, others 
also evaluated steroids in the treatment of optic neuritis and suggested a possible 
benefit (7,8).  In 1988, the results of a small trial of 12 patients with optic neuritis treated 
with high doses of intravenous methylprednisolone was published, all of whom showed 
improvement (9).  These studies paved the way for the ONTT, which has arguably 
influenced the treatment of acute optic neuritis more than any other published clinical 
trial (3). 
 
The Optic Neuritis Treatment Trial 
  
The ONTT included 457 patients between the ages of 18 and 46 with visual symptoms 
lasting 8 days or less and history and examination findings consistent with optic neuritis.  
Each patient was randomized to one of three study arms: placebo, 250 mg of 
intravenous methylprednisolone every 6 hours for 3 days followed by oral prednisone at 
1mg/kg for 11 days, or oral prednisone at 1mg/kg for 14 days.  The treatment regimen 
in both the intravenous and oral coticosteroid groups included a four-day oral taper.  
Treatment with intravenous methylprednisolone was associated with a more rapid 
recovery of visual function.  Methylprednisolone showed the most benefit within the first 
15 days of followup, but by 6 months, the visual outcome of the intravenous 
methylprednisolone group was only slightly better than placebo (3).  By one year, there 
was no difference in visual outcome in any of the groups (10).  Unexpectedly, oral 
prednisone treatment was associated with an approximately two-fold higher rate of 
recurrent optic neuritis during 6 to 24 months of followup (27%) than either the 
intravenous methylprednisolone group (13%) or the placebo group (15%).  At ten years, 
the rate of recurrence of optic neuritis was still higher in the oral prednisone group than 
in the IV methylprednisolone group, but was no longer significantly different from 
placebo (11).  At two years, the rate of progression to clinically-definite multiple 
sclerosis (CDMS) was lower in the intravenous methylprednisolone group than either 
the placebo or oral steroid groups, although there was no difference in the rates of 
multiple sclerosis between groups at 5 years (12).  During the trial, only two out of 151 
patients in the IV methylprednisolone group experienced serious, but transient, side 
effects: one with acute pancreatitis, and the other with acute transient depression. 
  
The results of the ONTT have been interpreted as showing that IVCS are well-tolerated 
and hasten visual recovery following acute optic neuritis, intermediate doses (1 
mg/kg/day) of oral predisone alone increase the risk of recurrence of optic neuritis, and 
intravenous steroids may delay the onset of CDMS within the first two years after optic 
neuritis. 
A recent meta-analysis of high-dose IVCS in the treatment of optic neuritis reiterated the 
findings of the ONTT in that it found no effect of IVCS on visual outcomes at 6 months 
or one year (13). 
 
Factors in the Response to Corticosteroid Treatment for Optic Neuritis 
No studies have suggested that any specific subgroup of patients with typical acute 
optic neuritis is more likely to benefit from treatment with corticosteroids than another.  
A recent reanalysis of data from the ONTT with regard to self-reported black 
race/ethnicity showed black patients had worse vision at the onset of optic neuritis and 
recovered at a faster rate than white patients, but the final vision was still worse in black 
patients.  No interaction between race/ethnicity and treatment modality was found for 
either intravenous or oral steroids.  Therefore, it is very unlikely that black race/ethnicity 
plays any significant role in the efficacy of steroid treatment for acute optic neuritis (14). 
 
Effect of Corticosteroids on the Risk of Optic Neuritis Recurrence 
  
The finding of an increased risk of optic neuritis recurrence following treatment with 
intermediate doses of oral prednisone in the ONTT has been the subject of criticism due 
to the purported lack of a plausible biological explanation, a marginal p value for the 
finding, disagreement with the results of an earlier published study, and alteration of the 
a priori assumptions of the trial to reach this conclusion (15).  Subsequent publications 
have addressed some of these criticisms.  A retrospective, single-center study of risk 
factors for idiopathic optic neuritis recurrence in Chinese patients found a higher rate of 
recurrence in patients with unilateral optic neuritis (40%, vs 12% for bilateral optic 
neuritis) and those treated with intermediate-dose (equivalent of ≤ 100 mg oral 
prednisone/day) corticosteroids (42%, vs 25% for > 100 mg/day; p = 0.045) (16).  The 
authors postulated that genomic effects of corticosteroids, mediated by alterations in 
gene transcription, are most prominent at doses ≤ 100 mg daily, while non-genomic 
effects predominate at doses > 100 mg daily, accounting for the difference in efficacy 
and optic neuritis recurrence risk between high-dose and intermediate-dose 
corticosteroids.  It is a now commonly accepted standard of practice that intermediate-
dose oral corticosteroids alone are not used in the treatment of typical acute optic 
neuritis. 
 
High-dose Oral Corticosteroids 
Although the ONTT showed no role for intermediate-dose (1 mg/kg daily) oral 
prednisone, there is limited data to support the use of high doses of oral prednisone in 
the treatment of optic neuritis (17).  Sixty patients were included in a single-center, 
  
randomized, placebo-controlled trial that evaluated oral methyprednisolone at a dose of 
500 mg daily for three days, followed by a 10 day oral taper.  There was a beneficial 
effect on vision at one and three weeks following the initiation of treatment, but not at 8 
weeks, and there was no increased risk of demyelinating events in the treated group at 
one year (17).  The potential for decreased costs and ease of administration associated 
with high-dose oral instead of intravenous corticosteroids has prompted interest in 
further research regarding the efficacy of high-dose oral corticosteroids for the treatment 
of optic neuritis.  A clinical trial has been completed evaluating optic neuritis recovery 
following randomized treatment with equivalent doses of intravenous or oral 
corticosteroids, although the results have not yet been published (NCT01524250, 
clinicaltrials.gov).  Based on currently available data, high-dose oral corticosteroids 
appear to be a reasonable consideration in the treatment of acute optic neuritis when 
IVCS are contraindicated or not available. 
 
Timing of Corticosteroid Administration in Optic Neuritis 
Determination of the optimal timing of corticosteroid treatment in optic neuritis has been 
elusive.  The ONTT addressed the effect of intravenous and oral steroids within 8 days 
of symptom onset, and the effects of more acute or delayed treatment of optic neuritis 
with corticosteroids are not fully known.  Treatment of optic neuritis with corticosteroids 
during the presumed hyperacute phase was evaluated in a prospective case series of 
patients with a history of optic neuritis and recurrence of pain in either eye (18).  Eight 
patients were evaluated in the presumed hyperacute stage of optic neuritis, prior to the 
  
onset of vision loss.  Five of the eight patients underwent MR imaging, and all five 
demonstrated optic nerve enhancement.  Treatment with high-dose intravenous steroids 
was given immediately, and no vision loss occurred in any of the patients, suggesting 
that corticosteroid treatment during the painful phase of presumed optic neuritis, before 
the onset of vision loss, may prevent vision loss. 
 
Corticosteroids in the Treatment of Atypical Optic Neuritis 
Atypical optic neuritis may be differentiated from typical optic neuritis by progressive 
unilateral or bilateral visual loss, poor visual recovery, lack of eye pain, hemorrhages or 
exudates on funduscopic examination, and relapse after steroid withdrawal (19).  
Atypical optic neuritis may be a manifestation of neuromyelitis optica (NMO), 
autoimmune optic neuropathy, chronic relapsing inflammatory optic neuropathy 
(CRION), neuroretinitis, or optic neuropathy associated with systemic diseases such as 
connective tissue diseases, vasculitides, or sarcoidosis.  Although data from 
prospective randomized clinical treatment trials do not exist for corticosteroids for 
atypical optic neuritis, retrospective case series and expert opinion suggest that visual 
outcomes may be poor if left untreated (1), and high-dose IVCS are often the preferred 
treatment. 
Optic neuritis associated with NMO is typically treated with high-dose IVCS, a practice 
adopted from the treatment of idiopathic optic neuritis, despite the lack of a clinical trial 
evaluating its efficacy specifically in NMO (20).  The efficacy of high-dose IVCS (IVCS) 
was recently evaluated in comparison with plasma exchange (PLEX) plus IVCS in acute 
  
NMO relapses (21).  This nonrandomized retrospective study found disability scale 
scores were more likely to be at or below their baseline in the PLEX plus IVCS group 
than in the IVCS alone group at 6-18 months followup.  Despite relapses of NMO being 
less responsive to high-dose corticosteroids than relapses of multiple sclerosis (21), 
high-dose IVCS are considered standard therapy in the treatment of NMO relapses. 
Patients with autoimmune optic neuritis, which has included patients with laboratory 
evidence of a systemic collagen vascular disease, in one series responded very 
favorably and often dramatically to high-dose corticosteroids (22).  In a retrospective 
case series of 15 patients considered to have CRION, which is considered to differ from 
typical optic neuritis by its steroid-dependent and relapsing course, all were described 
as having a “clear and prompt response to treatment with systemic corticosteroids” (23).  
High-dose intravenous or oral corticosteroids are considered as part of the treatment 
guidelines for recurrent neuroretinitis, which typically presents with optic disc edema 
followed by an exudative maculopathy (“macular star”) (24).  Infectious causes of optic 
neuritis are rare, but may include syphilis, Lyme disease, tuberculosis, West Nile virus, 
and others (25).  There are no clinical trial data on the effect of corticosteroids in 
infectious optic neuritis.  High-dose corticosteroids are considered a first-line treatment 
for most forms of atypical optic neuritis. 
 
Corticosteroids in Pediatric Optic Neuritis 
Unlike in adult optic neuritis, pediatric optic neuritis most often presents with 
funduscopic abnormalities, including optic disc edema and retinal exudates.  A greater 
  
proportion of patients with severe and/or bilateral vision loss is also characteristic of 
pediatric optic neuritis (26,27).  Children with optic neuritis tend to recover faster than 
adults and a higher percentage involve secondary causes than in adults (28).  Despite 
the lack of prospective clinical data in children to support its use, high-dose intravenous 
methylprednisolone is considered first-line treatment for pediatric optic neuritis by 
extension from the ONTT, as affected children often present with impairment of visual 
acuity severe enough to justify its use.  Following IVCS, a prolonged oral corticosteroid 
taper over 2-6 weeks is common, as some experts believe there is an increased rate of 
relapse with early cessation of corticosteroids (27,29,30).  One recent small 
retrospective study of 26 consecutive pediatric patients with optic neuritis treated for 3 
days with intravenous methylprednisolone compared those treated with an additional 
two weeks of oral corticosteroids to those treated for more than two additional weeks.  
Final visual acuity, side effects, and relapse rates did not differ between the two groups 
with a mean follow-up of 70 weeks.  This study included potential for selection bias with 
longer courses of corticosteroids given to patients exhibiting poor recovery. 
 
Future Research 
Despite an abundance of useful data gathered from the ONTT and other clinical trials 
and case series, important questions remain regarding the use of corticosteroids in the 
treatment of optic neuritis, such as the optimal dose, timing, specific formulation, and 
route of administration (31,32) and whether there may be a subgroup of patients with 
  
optic neuritis in whom high-dose corticosteroid treatment results in persistent, long-term 
clinical improvement. 
A recently published review on the investigation of acute optic neuritis called for 
consensus in the investigation of patients with acute optic neuritis in the context of new 
imaging, laboratory and electrophysiological techniques (33).  Organized 
implementation of new techniques in the evaluation of optic neuritis is likely to lead to 
meaningful new data, which could help answer lingering questions regarding the role of 
corticosteroids in the treatment of optic neuritis. 
 
Conclusion 
Two main benefits are often cited as rationale for treatment of acute typical optic neuritis 
with IVCS: hastening of visual recovery and a lower rate of progression to clinically-
definite multiple sclerosis (CDMS) at 2 years, but not at 5 years (3,34).  The potential for 
bias confounding interpretation of the data suggesting a lower rate of progression to 
CDMS in the short-term has been raised (15). 
As with any treatment, the approach to whether or not to implement a specific therapy 
relies on an accurate understanding of the potential risks and benefits.  The ONTT 
demonstrated relatively good tolerability of high-dose intravenous methylprednisolone, 
although patients should be informed of potential adverse effects, including sleep 
disturbances, mood changes, gastrointestinal upset, facial flushing, psychosis, and 
hyperglycemia (35). 
  
After a discussion with the patient regarding potential risks and benefits, it is reasonable 
to recommend high-dose IVCS to patients with acute optic neuritis with bilateral or 
significant unilateral vision loss, severe pain, T2 hyperintensities on MRI that predict a 
higher short-term risk of development of CDMS, or features of atypical optic neuritis 
(Figure 2).  High-dose corticosteroids may help prevent poor visual outcomes in atypical 
optic neuritis, but the excellent visual prognosis in typical optic neuritis coupled with the 
lack of definitive permanent benefits of high-dose IVCS make the treatment of typical 
optic neuritis optional, but helpful in selected cases characterized by significant vision 
loss, severe pain, and/or T2 white matter hyperintensities on brain MRI. 
 
Key Points 
• IVCS hasten the recovery of visual function in typical acute optic neuritis and 
may decrease the risk of development of CDMS at 2 years, but not at 5 or 10 
years 
• It is reasonable to offer high-dose IVCS in patients with typical acute optic 
neuritis with significant vision loss, severe pain, and/or T2 white matter 
hyperintensities on brain MRI 
• No permanent beneficial effects of high-dose IVCS have been demonstrated in 
typical acute optic neuritis trials, emphasizing the role of IVCS as an optional, but 
potentially very helpful, treatment for typical acute optic neuritis 
• Untreated atypical optic neuritis may lead to irreversible vision loss and urgent 
treatment with corticosteroids may help prevent poor visual outcomes 
  
• Intermediate-dose oral corticosteroids (1mg/kg/day prednisone equivalent) have 
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Figure 1.  MRI findings associated with optic neuritis.  A) T1 post-contrast fat 
suppressed axial images showing enhancement of the proximal intraorbital portion of 
the right optic nerve (arrows).  B)  T1 post-contrast fat suppressed coronal images 
showing enhancement of the intraorbital right optic nerve.  C)  T2 FLAIR axial brain 
sequence in the same patient showing areas of T2 hyperintensity in the periventricular 
cerebral white matter in a pattern consistent with the patient’s known multiple sclerosis.  
None of the lesions were enhancing on post-contrast images. 
Figure 2.  Weighing the potential risks and benefits of high-dose IV corticosteroid 
treatment of acute optic neuritis.  High-dose corticosteroids are most likely to be helpful 
in patients with optic neuritis with significant vision loss, significant pain, acute symptom 
onset (< 8 days), T2 hyperintense white matter lesions on brain MRI, or features of 
atypical optic neuritis.  The clinician must weigh the potential for benefit against possible 
adverse effects before making a treatment recommendation.  Cost and availability of 
treatment may not directly impact the risk:benefit ratio, but may influence the advisability 
of treatment. 
